BTL Announces Expanded Clearances and Versatility for EMSELLA® Platform
TORONTO, June 5, 2025 /CNW/ -- BTL, a global leader in non-invasive medical solutions, proudly announces expanded Health Canada License for its revolutionary EMSELLA® platform, reinforcing its leadership in pelvic health and intimate wellness.
FDA-cleared and Health Canada-licensed for the treatment of urinary incontinence in both men and women, Emsella now also holds an additional Health Canada license and CE-mark certification for enhancing sexual function in patients experiencing somatic sexual arousal disorders caused by weak pelvic floor muscles.
Backed by robust clinical outcomes, EMSELLA continues to redefine non-invasive care across pelvic health and sexual function. Key findings include:
Sexual Dysfunction Statistics:
76% improvement in sexual satisfaction and desire 1
60% improvement in orgasm quality 1
37% improvement in maintaining erection during intercourse 2
48% improvement in pelvic muscle endurance 3
When compared to other modalities, EMSELLA outperforms significantly:
7x more effective than pelvic floor muscle training
"EMSELLA continues to surpass expectations—not just in treating incontinence but in restoring confidence, and overall quality of life," said David Chmel, CEO of BTL North America. "These expanded clearances and clinical outcomes validate what providers and patients have long experienced: EMSELLA delivers meaningful results in a way that's accessible, comfortable, and non-invasive."
Shari Caplan, MD, CCFP, FCFP, FAARM, a board-certified expert in functional, integrative , anti-aging, and intimate health said, "We're witnessing a complete shift in how pelvic and sexual health is approached. Patients are achieving results we used to think were only possible with surgery or years of therapy. EMSELLA has become a go-to solution in my practice for urinary control and sexual wellness for both men and women."
As the demand for intimate wellness treatments rises, EMSELLA remains uniquely positioned as an effective and versatile tool for addressing some of the most intimate and often under-discussed health concerns.
To learn more about EMSELLA, visit www.emsella.com.
About BTL
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 350+ patents and over 580 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.
For more information, visit www.bodybybtl.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally Français
Product: Various nitrous oxide products Issue: Health products – Product safety; Unauthorized product What to do: Do not inhale nitrous oxide products for recreational purposes. If you use prescription nitrous oxide recreationally and experience side effects, seek medical attention immediately. Affected products Various nitrous oxide products. Examples of seized products include: Bamboozle Need Whip Primewhip Primewhip XL Space Gas Issue Health Canada is warning consumers about the serious health risks, including death, of inhaling nitrous oxide products, also known as laughing gas and by various street names, such as "whippets," "hippy crack," "NOS" and "nang," for recreational purposes. In Canada, nitrous oxide sold for inhalation is a drug and can only be administered by an authorized health care professional for legitimate and safe uses, such as in medical and dental procedures for sedation and pain relief. It is also in cream dispensers and other food tools where it is not meant to be inhaled. When inhaled—or "huffed" —nitrous oxide can cause euphoria and relaxation. It can also cause serious adverse effects such as: loss of consciousness and in some cases, death birth defects anemia, vitamin B12 deficiency impaired bowel and bladder function confusion, agitation, delusions, hallucinations, paranoia and depression increased heart rate, palpitations, low blood pressure, heart attack and stroke lack of oxygen in the body (asphyxia), blood clots in the extremities and in the lungs, and air leaks into the space between the lung and chest wall (pneumothorax) tingling, numbness and weakness of the limbs and extremities (fingers and toes), uncoordinated walking and falls nerve damage, spinal cord degeneration, prolonged pain and, in severe cases, permanent paralysis Repeated use increases the likelihood of severe outcomes and may result in lasting neurological damage, even after stopping use. Regular use can also lead to addiction and withdrawal symptoms. Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited. However, Health Canada is aware that these products are being sold online and in retail stores. These products may be deceptively labelled: as "whip cream chargers," in flavours, which are not permitted, in stores you would not expect to find whipped cream chargers; and in large containers you would not expect for dispensing whipped cream. Health Canada has not reviewed these products, which are regulated as drugs, for safety, efficacy or quality. Also, they could be contaminated in ways that create additional health risks when inhaled. Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes. Health Canada has seized several unauthorized nitrous oxide products and has worked with Canada Border Services Agency (CBSA) to stop unauthorized shipments from entering the country. The Department will continue to take action to stop the sale of unauthorized products and to work with CBSA to help prevent further importations. What you should do
Cision Canada
3 hours ago
- Cision Canada
Public Advisory - One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only) Français
Product: Seasonique (DIN 02346176) Issue: Health products - Product quality What to do: Do not skip doses or stop taking Seasonique. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next blue-green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. Affected products: Issue Teva Canada Ltd. is recalling one lot of Seasonique prescription birth control due to the possibility of having an extra row of yellow pills in tray 1 and/or 2 of the blister cards, where there should be none. This may increase the risk of pregnancy. When packaged correctly, as shown in the picture, Seasonique pills come in extended-cycle tablet dispensers, each containing a 13-week (91-day) supply of pills divided in three blister cards: Tray 1 and Tray 2 each contain a blister card with 28 blue-green tablets (levonorgestrel and ethinyl estradiol) Tray 3 contains a blister card with 35 tablets: 28 blue-green tablets (levonorgestrel and ethinyl estradiol) and 7 yellow tablets (ethinyl estradiol) Users can expect to have four periods a year, with bleeding occurring while taking the yellow pills. Seasonique should be taken daily unless otherwise directed by your prescriber. Taking the pills in the proper order, according to the product instructions, is important for preventing pregnancy. Taking the wrong pill or a pill out of order could lead to an unplanned pregnancy or other side effects, including spotting and irregular bleeding. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions. The Department will inform the public if any new health risks are identified. What you should do: Do not stop taking Seasonique. Do not skip taking any blue–green pills. Check your package. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return it to your pharmacy for a replacement or an alternative product. If you cannot get to a pharmacy right away, take the next blue–green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. If you are unsure whether your package contains the correct pills, talk to your pharmacist. If you took a yellow pill instead of a blue-green pill from Tray 1 and/or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional. Talk to a health care professional if you have any other questions or concerns about your birth control product. Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at [email protected] if you have questions about this recall. Report any health product-related adverse reactions or complaints to Health Canada
Cision Canada
6 hours ago
- Cision Canada
Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
TORONTO, June 6, 2025 /CNW/ - Sunday, June 8, 2025 — National advocacy organization Obesity Matters will host the Your Health Matters Summit 2025 at the historic Old Mill Toronto, with virtual access available across Canada. This one-day, community-powered event is creating space for real stories, honest conversations, and stigma-free care — putting people, not just conditions, at the center of health and wellness. With the theme "Inspire Change. Build Connection. Advance Wellness.", the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support. "Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity," says Priti Chawla, Executive Director of Obesity Matters. "This summit is about rewriting the narrative — one story, one connection, one person at a time." Program highlights include: Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience Dr. Megha Poddar on hormone health across life stages Dr. Peter Selby facilitating a storytelling session with patient advocates Dr. David Macklin on Resilience… The Secret Skill to Success A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters. "We can't let outdated ideals or social media define what health looks like," says Dr. Sandy Van. "In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind." "For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment." — Sandra Elia, Chair, Obesity Matters
